TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03658252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted education
Description: Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online disease specific forum
Description: An invitation to join an online moderated disease specific social forum
Study: NCT02333318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injection
Description: Colorless, transparent liquid in water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injection
Description: Colorless, transparent liquid in water for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study: NCT01628367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Graft Placement
Description: Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Membrane placement
Description: A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collagen plug placement
Description: A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT01628367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medications
Description: Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications
Description: Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
Study: NCT02594800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
Study: NCT03883802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foxy-5
Description: Lyophilized powder for solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: 6 months treatment regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: 6 months treatment regimen
Study: NCT02594800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
Study: NCT03100721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE+Physiotherapy
Description: Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy cover kinesitherapy and exercises techniques.
Study: NCT03883802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumour resection (colon cancer surgery)
Description: Surgical removal of patients colon cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumour resection (colon cancer surgery)
Description: Surgical removal of patients colon cancer
Study: NCT00354692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate and Iron sucrose
Study: NCT04671082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TID
Study: NCT05111106

Intervention type: DEVICE
Intervention: Symfony IOL
Description: Implantation of Intraocular lens with extended depth of focus.

Intervention type: DEVICE
Intervention: Symfony IOL
Description: Implantation of Intraocular lens with extended depth of focus.

Intervention type: DEVICE
Intervention: Symfony IOL
Description: Implantation of Intraocular lens with extended depth of focus.
Study: NCT01812330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After 600mg loading dose, 75mg or 150mg Qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After 600mg loading dose, 75mg or 150mg Qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg Bid
Study: NCT02065609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Trastuzumab Human Dosimetry and Safety
Description: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Trastuzumab Human Dosimetry and Safety
Description: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 Positive Lesion Detection and Safety
Description: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 Positive Lesion Detection and Safety
Description: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
Study: NCT04105751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Communication System
Description: Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
Study: NCT00554398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0518 400mg twice a day
Description: Raltegravir, MK-0518
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT01744678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blue-wavelength enriched ceiling light
Description: Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mild exercise
Description: Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
Study: NCT01749592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implant
Description: Surgical implantation of a cochlear implant device
Study: NCT03594149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 500 mg/d p.o.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT02295007

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: text message
Study: NCT00600041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
Study: NCT04007705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory and low FODMAPs diet
Description: Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General healthy eating
Description: Healthy eating counseling according to the World Health Organization
Study: NCT00600041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical infusion manner like experimental arm
Study: NCT00462735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
Study: NCT01350570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture group1, acupoints ST25 and BL25 will be used in this trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture group2
Description: Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
Study: NCT00462735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients.
Study: NCT01846715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Implantation of SRC
Study: NCT01335750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #1
Description: B\&L Renu Fresh Multipurpose Solution
Study: NCT04514081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide; Decitabine; Camrelizumab
Description: Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine+Camrelizumab
Description: Decitabine+Camrelizumab
Study: NCT00655109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine
Description: Ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Ophthalmic Solution
Study: NCT00898521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGD
Description: DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area.
Study: NCT01714076

Intervention type: OTHER
Intervention: cohort isolation
Description: all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
Study: NCT01080404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: A standardized laparoscopic gastric bypass using Roux-en-Y technique
Study: NCT01335750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #1
Description: B\&L Renu Fresh Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #1
Description: B\&L Renu Fresh Multipurpose Solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multipurpose Solution #1
Description: B\&L Renu Fresh Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #2
Description: Optifree Replenish Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #2
Description: Optifree Replenish Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #2
Description: Optifree Replenish Multipurpose Solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multipurpose Solution #2
Description: Optifree Replenish Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlipurpose Solution #3
Description: Ciba ClearCare Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlipurpose Solution #3
Description: Ciba ClearCare Multipurpose Solution
Study: NCT01350570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture group3
Description: All acupoints used in acupuncture group1 and group2 will be used in this group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Loperamide will be used in this group for a dose of 2mg a time, three time a day.
Study: NCT04382287

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remin Pro® and MI Paste Plus®
Description: Te toothastes were applied at home twice a day over the six anterior upper primary teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remin Pro® and MI Paste Plus®
Description: Te toothastes were applied at home twice a day over the six anterior upper primary teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remin Pro® and MI Paste Plus®
Description: Te toothastes were applied at home twice a day over the six anterior upper primary teeth
Study: NCT02341898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational programme for all nurses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and structured support for nominated key nurses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and structured support for nominated key nurses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facultative train-the-trainer module for key nurses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed study material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed study material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed study material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive material (poster, mugs etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive material (poster, mugs etc.)
Study: NCT04123626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection
Study: NCT01335750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlipurpose Solution #3
Description: Ciba ClearCare Multipurpose Solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mutlipurpose Solution #3
Description: Ciba ClearCare Multipurpose Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #4
Description: Saline Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #4
Description: Saline Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #4
Description: Saline Solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multipurpose Solution #4
Description: Saline Solution
Study: NCT04126265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assisted colonoscopy
Description: The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
Study: NCT03250039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 14C labeled PF-04965842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Absolute Bioavailability
Description: Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
Study: NCT03094286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
Study: NCT04140201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Drugs that lower lipid level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200mg
Description: Drugs that lower lipid levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Drugs that lower lipid levels
Study: NCT03504241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived Mesenchymal Stromal Cells
Description: These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
Study: NCT04123626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham procedure
Description: Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
Study: NCT02989324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MisoprostoL
Description: Vaginal MisoprostoL
Study: NCT05562362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021, sparsentan
Description: RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021, sparsentan
Description: RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021, sparsentan
Description: RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
Study: NCT00091351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00524368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (rtv)
Description: DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (rtv)
Description: DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.